MRK.DE - Merck Kommanditgesellschaft auf Aktien

XETRA - XETRA Delayed Price. Currency in EUR
93.34
-0.59 (-0.63%)
At close: 5:35PM CEST
Stock chart is not supported by your current browser
Previous Close93.93
Open94.20
Bid0.00 x 6700
Ask0.00 x 11200
Day's Range93.22 - 94.62
52 Week Range90.00 - 115.20
Volume444,167
Avg. Volume562,620
Market Cap40.67B
BetaN/A
PE Ratio (TTM)24.33
EPS (TTM)3.84
Earnings DateNov 9, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Merck KGaA breached its 50 day moving average in a Bearish Manner : MRK-DE : October 18, 2017
    Capital Cube5 days ago

    Merck KGaA breached its 50 day moving average in a Bearish Manner : MRK-DE : October 18, 2017

    Categories: Europe Stock Alerts Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Merck KGaA. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bearish 50 ... Read more (Read more...)

  • TheStreet.com13 days ago

    Pfizer Pops in Pre-Market After Group Considers Consumer Healthcare Sale

    Pfizer's consumer healthcare division has 10 brands, including Advil and Centrum, that had $100 million or more in sales last year.

  • Merck KGaA breached its 50 day moving average in a Bearish Manner : MRK-DE : October 2, 2017
    Capital Cube21 days ago

    Merck KGaA breached its 50 day moving average in a Bearish Manner : MRK-DE : October 2, 2017

    Categories: Europe Stock Alerts Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Merck KGaA. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bearish 50 ... Read more (Read more...)

  • Pfizer-Merck KGaA Skin Cancer Drug Bavencio Gets EU Approval
    Zackslast month

    Pfizer-Merck KGaA Skin Cancer Drug Bavencio Gets EU Approval

    Pfizer and German partner Merck KGaA's Bavencio secures an EU approval for metastatic Merkel cell carcinoma. The company also expects to make the drug commercially available within a month.

  • Reuterslast month

    Merck KGaA, Pfizer's cancer drug Bavencio gets EU nod

    European regulators on Thursday granted market approval for Merck KGaA and Pfizer's immuno-oncology drug Bavencio to treat a rare and aggressive type of skin cancer called Merkel cell carcinoma. In May, ...

  • PR Newswirelast month

    Merck KGaA, Darmstadt, Germany Announces Recipients of the Grant for Growth Innovation 2017

    Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced the recipients of the Grant for Growth Innovation (GGI) for 2017. The winners were announced at an awards presentation meeting organized by Merck KGaA, Darmstadt, Germany during the 10th International Meeting of Pediatric Endocrinology, in Washington, United States.

  • Merck KGaA – Value Analysis (XETRA:MRK) : September 12, 2017
    Capital Cubelast month

    Merck KGaA – Value Analysis (XETRA:MRK) : September 12, 2017

    Categories: Europe Value Analsysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Merck KGaA a score of 56. Our analysis is based on comparing Merck KGaA with the following peers – Bayer AG, Hutchison China MediTech Limited, Sanofi and Chemical Works of Gedeon Richter Plc (BAYN-DE, HCM-GB, SNW-DE and RIG2-DE). Investment Outlook Merck KGaA has a fundamental score of ... Read more (Read more...)

  • Nestle's Growth Supplements
    Bloomberglast month

    Nestle's Growth Supplements

    Merck's consumer-health business isn't an obvious way to buy durable growth.

  • PR Newswirelast month

    Merck KGaA, Darmstadt, Germany, Set to Join Forces with Project Data Sphere to Pioneer Global Oncology Big Data Alliance

    Merck KGaA, Darmstadt, Germany, a leading science and technology company has announced that it will enter into a strategic collaboration with Project Data Sphere LLC, an independent, not-for-profit initiative of the CEO Roundtable on Cancer's Life Sciences Consortium, to jointly lead the Global Oncology Big Data Alliance (GOBDA). This was announced at the signing of a Memorandum of Understanding yesterday, to coincide with Merck KGaA, Darmstadt, Germany's, Award Ceremony announcing the recipients of its 2017 Grant for Oncology Innovation, held during the annual European Society for Medical Oncology Congress (ESMO 2017) in Madrid, Spain.

  • Merck KGaA breached its 50 day moving average in a Bullish Manner : MRK-DE : September 11, 2017
    Capital Cubelast month

    Merck KGaA breached its 50 day moving average in a Bullish Manner : MRK-DE : September 11, 2017

    Categories: Europe Stock Alerts Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Merck KGaA. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bearish 50 ... Read more (Read more...)

  • Reuterslast month

    Germany's Merck hires JP Morgan to sell consumer health

    FRANKFURT/LONDON, Sept 8 (Reuters) - Germany's Merck KGaA has hired JP Morgan to sell its consumer health business, which includes brands such as Seven Seas vitamins and could be worth around $4.5 billion. The family-controlled drugmaker said on Tuesday it was considering selling the business, whose sales of over-the-counter medicines and vitamin supplements are about $1 billion a year, to help fund research into higher-margin prescription drugs.

  • PR Newswirelast month

    Merck KGaA, Darmstadt, Germany, ‘Grant for Oncology Innovation’ Awards Recognize Recipients for Pushing Boundaries in Oncology Research

    DARMSTADT, Germany , September 10, 2017 /PRNewswire/ -- Not intended for UK-based media €1 million grant funded by Merck KGaA, Darmstadt, Germany , supports research with the potential to advance implementation ...

  • The Wall Street Journal2 months ago

    Germany’s Merck Puts Consumer Drugs Business on the Block

    Merck KGaA Chief Executive Stefan Oschmann put the Germany company’s consumer-health unit on the block in a move that will focus its health-care activities on the riskier business of developing prescription ...

  • Slimming Down Will Flatter Merck KGaA
    Bloomberg2 months ago

    Slimming Down Will Flatter Merck KGaA

    Ditching its laggard consumer-products unit can help it focus on its new cancer drug.

  • MarketWatch2 months ago

    Merck rises 2% after health business is put up for sale

    Shares of Merck KGaA climbed 2% in Frankfurt on Tuesday after the German pharmaceutical major put its consumer health business up for sale. In a statement the company said it's "preparing strategic ...

  • TheStreet.com2 months ago

    Merck KGaA Plans Consumer Healthcare Sale After Strategic Review

    Germany's Merck KGaA is looking to sell its $1 billion consumer healthcare unit after a group-wide strategic review.

  • Market Realist2 months ago

    Pfizer’s Immuno-Oncology Clinical Program’s Long-Term Growth Potential

    The success in ongoing clinical trials could help Pfizer and Merck KGaA file for label expansion and approval of the new indications for Bavencio.

  • Market Realist2 months ago

    How Merck Performed in 2Q17

    In 2Q17, Merck reported GAAP earnings per share of $0.71 compared to $0.56 in 1Q17.

  • The Wall Street Journal2 months ago

    [$$] U.K. Biotech Macrophage Gets Merck Backing

    Macrophage Pharma Ltd. has added Merck Ventures to its Series A syndicate ahead of plans to launch clinical studies of a new approach to orchestrating an immune system attack on cancer.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of MRK.DE earnings conference call or presentation 3-Aug-17 12:00pm GMT

    Half Year 2017 Merck KGaA Earnings Call

  • Merck KGaA (MKGAF) Q2 Earnings Up Y/Y
    Zacks3 months ago

    Merck KGaA (MKGAF) Q2 Earnings Up Y/Y

    Merck KGaA (MKGAF) reports second-quarter results with earnings rising year-over-year and sales registering organic growth.

  • What's in the Cards for Merck KGaA (MKGAF) in Q2 Earnings?
    Zacks3 months ago

    What's in the Cards for Merck KGaA (MKGAF) in Q2 Earnings?

    Merck KGaA???s (MKGAF) Life Science segment is expected to perform well following the approval of Bavencio.

  • PR Newswire3 months ago

    EMA's CHMP Issues Positive Opinion for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma

    DARMSTADT, Germany and NEW YORK , July 20, 2017 /PRNewswire/ -- Not intended for UK-based media     If approved,   avelumab   could   be   the   first   immunotherapy   treatment   indicated   for   this ...

  • EU charges Merck KGaA, GE, Canon over merger rules
    Reuters4 months ago

    EU charges Merck KGaA, GE, Canon over merger rules

    General Electric (GE.N), German drugmaker Merck KGaA (MRCG.DE), and Japan's Canon (7751.T) risk hefty fines after EU antitrust regulators accused them of providing misleading information during separate merger deals. The European Commission said on Thursday that it had sent three separate charge sheets known as statements of objections to General Electric, Merck KGaA and Canon after investigations showed breaches of the bloc's merger rules. While the charges will not affect the EU approvals of the deals, they could lead to fines of up to 1 percent of global revenue for Merck KGaA and General Electric, and up to 10 percent for Canon.

  • Reuters4 months ago

    EU charges Merck KGaA, GE, Canon over merger rules

    General Electric, German drugmaker Merck KGaA, and Japan's Canon risk hefty fines after EU antitrust regulators accused them of providing misleading information during separate merger deals. The European Commission said on Thursday that it had sent three separate charge sheets known as statements of objections to General Electric, Merck KGaA and Canon after investigations showed breaches of the bloc's merger rules. While the charges will not affect the EU approvals of the deals, they could lead to fines of up to 1 percent of global revenue for Merck KGaA and General Electric, and up to 10 percent for Canon.